NIPT is a blood test taken from the mother's arm. From around 5 weeks of pregnancy, fragments of DNA from the placenta begin to circulate in the mother's blood — by 10 weeks, the fraction is usually high enough (around 4 percent or more) for a lab to separate the fetal fragments out, count chromosomes within them, and report whether the count for chromosome 21, 18 or 13 looks normal or extra. The placenta carries the same DNA as the baby in almost all cases, so reading placental fragments is a very good proxy for reading the baby's chromosomes — without ever needing a needle near the womb.

Older serum screening tests like the double or triple marker measure hormone levels (PAPP-A, hCG, AFP, estriol, inhibin-A) in the mother's blood and combine those with maternal age and NT scan measurements to estimate risk. That is an indirect, statistical approach. NIPT is a direct read of the actual fetal DNA, which is why its accuracy is so much higher.

What NIPT does not do is sample fetal cells themselves. It samples the DNA fragments only, and it only sequences a defined set of chromosomes — typically 21, 18, 13 and the sex chromosomes, with optional add-on panels for select microdeletions. It cannot detect structural defects of the heart, brain or spine (those are picked up on the anomaly scan at 18 to 20 weeks), cannot detect single-gene conditions like thalassaemia or cystic fibrosis (those need targeted gene testing), and cannot tell you anything about chromosomes or regions not included in the panel. For how to read a typical Indian scan and lab report alongside NIPT, see Understanding Scans, Labs & Reports: A Complete India Pregnancy Guide.

The earliest reliable window for NIPT is 10 weeks of pregnancy, calculated from the first day of the last menstrual period and ideally confirmed on the dating scan. Before 10 weeks, the fraction of fetal DNA circulating in the mother's blood is often too low — a result returned at 8 or 9 weeks can be a no-call (the lab cannot give a result and a repeat sample is needed) or, more rarely, falsely reassuring. From 10 weeks onwards through the rest of pregnancy, NIPT performs well; in practice most women who choose it are tested between 10 and 14 weeks so that any abnormal result still leaves time for early diagnostic confirmation with chorionic villus sampling (CVS) or amniocentesis.

NIPT is most strongly indicated when the chance of a chromosomal condition is higher than the general population baseline. That includes advanced maternal age (35 years or older at delivery), an abnormal NT scan with nuchal translucency above 3.5 mm or with absent nasal bone, a high-risk double or triple marker result, a previous pregnancy with a confirmed chromosomal abnormality, a known family history of a genetic disorder, an IVF pregnancy (where the underlying chromosomal risk is a little higher), and twin pregnancies (where invasive testing like amniocentesis carries higher procedural risk, so an accurate non-invasive screen is especially useful first).

NIPT is also increasingly chosen electively by women with no specific risk factor, for the reassurance of an early high-accuracy screen — particularly if they would prefer to avoid amniocentesis unless a clear high-risk result demands it. That is a valid choice. The flip side is that some couples prefer not to do any chromosomal screening at all, because they would continue the pregnancy regardless of the result — that too is a valid choice, and screening should not be presented as automatic. For broader pregnancy planning context, see What to Expect Week by Week During Pregnancy.

The headline accuracy figure most often quoted for NIPT — around 99 percent — is specifically for the detection rate of Down syndrome (trisomy 21) in singleton pregnancies. That number is honest for trisomy 21, and it is meaningfully higher than the 80 to 85 percent detection rate of the double marker, the roughly 70 percent of the triple marker, or the 80 to 85 percent of the quadruple marker. NIPT also has a much lower false-positive rate (about 0.1 percent for trisomy 21), which means far fewer women are sent for an unnecessary amniocentesis on the basis of a falsely high-risk screen.

For other conditions on the standard panel, accuracy is still high but slightly lower. Detection of trisomy 18 is around 97 percent, trisomy 13 around 90 percent. Sex chromosome abnormalities (Turner syndrome 45,X, Klinefelter 47,XXY, triple X 47,XXX, XYY) are reported at 90 to 95 percent detection but with somewhat higher false-positive rates, partly because the maternal DNA itself can carry sex chromosome variations that confuse the analysis. Microdeletion panels — small missing pieces of specific chromosomes, such as 22q11 deletion (DiGeorge syndrome) — vary widely; published detection rates are lower and false-positive rates much higher, which is why many labs and clinicians offer microdeletion add-ons cautiously, with explicit counselling that a positive result is much more likely to be a false alarm than for the main trisomies.

There are also some technical situations where NIPT can give a no-call or an unreliable result. Maternal obesity (because the fetal DNA fraction is diluted in a larger blood volume), very early gestational age, low fetal fraction for unknown reasons, vanishing twin syndrome where the lost twin's DNA confuses the read, certain maternal medical conditions, and maternal chromosomal mosaicism can all interfere. A no-call result usually means a repeat sample a few weeks later or, if it persists, a discussion about going directly to a diagnostic test.

This is the single most important thing to understand about NIPT. It is a screening test, not a diagnostic one. A high-risk NIPT result does not mean the baby has the condition — it means the probability is high enough that the next step is offered, which is a diagnostic test (CVS or amniocentesis) that actually samples fetal cells and gives a definitive yes or no. The false-positive rate for trisomy 21 is low at around 0.1 percent, but at the population level that still translates into real numbers of women who get a high-risk NIPT and a normal amniocentesis.

Equally, a low-risk NIPT result is reassuring but not a guarantee. It tells you that the specific conditions on the panel are unlikely; it does not tell you anything about conditions outside the panel, structural defects of the heart, brain, kidneys or spine, single-gene disorders, or problems that develop later in pregnancy. The anomaly scan at 18 to 20 weeks still needs to happen, the third-trimester growth scans still need to happen, and routine antenatal care continues exactly as in any pregnancy.

The clinical pathway for an abnormal NIPT result in India is fairly standard: a counselling visit (often with a genetic counsellor if the lab has one, otherwise with the referring OB-GYN), an explanation of what the specific high-risk result actually means in terms of probability, and an offer of CVS at 11 to 14 weeks or amniocentesis at 16 weeks onwards for definitive confirmation. Termination decisions are never made on the basis of a screening test alone — they are made, if a couple chooses to consider one, only after diagnostic confirmation and within the Medical Termination of Pregnancy Act framework.

Several international NIPT brands are available through Indian labs, including Verifi, PrenaTest, MaterniT21, IriSure and various indigenous panels marketed under lab-specific names. The actual sequencing for most panels is done either in an Indian central lab (Thyrocare, Metropolis, SRL Diagnostics, Dr Lal PathLabs and a few others run their own sequencing facilities) or shipped overseas, with results returned in 7 to 14 days either way.

Cost varies by lab, by panel size, and by city. The basic panel covering trisomy 21, 18 and 13 is usually priced at around 12,000 to 18,000 rupees. Adding the sex chromosome panel takes it to roughly 15,000 to 22,000 rupees. Extended panels with select microdeletions are in the 22,000 to 30,000 rupee range, and premium whole-genome or whole-chromosome panels can reach 28,000 to 35,000 rupees. Twin pregnancy NIPT is priced higher and usually with reduced microdeletion coverage because the technical complexity is greater.

Insurance coverage in India is inconsistent. NIPT is usually not covered by basic health insurance policies unless the pregnancy is documented as high-risk — for example with an abnormal NT scan, a high-risk double or triple marker, advanced maternal age, or a previous pregnancy with a chromosomal abnormality. Even where coverage exists, prior authorisation is often required, and the reimbursement is partial. Most women in India still pay for NIPT out of pocket. When budgeting, it is worth knowing that the basic trisomy 21, 18 and 13 panel captures most of the conditions that are clinically actionable; the more expensive extended panels add coverage for conditions where the test is less accurate and the practical decisions are harder.

The Pre-Conception and Pre-Natal Diagnostic Techniques Act, 1994, prohibits the disclosure of fetal sex by any prenatal technique, regardless of how the information is technically obtained. Because NIPT analyses sex chromosomes as part of its standard panel, the test does, technically, identify fetal sex along the way. Indian NIPT-compliant labs handle this by redacting the sex chromosome result on the report released to parents — the chromosomal aneuploidy result for the sex chromosomes is still flagged if abnormal, but the specific male or female read is removed before the report is shared.

Choosing a PC-PNDT-compliant lab is not optional in India. A compliant lab will be registered with the appropriate authority, will require a signed Form F at the time of every NIPT request (a standard form that documents the indication for the test and is part of the audit trail), will provide a report that contains no line referring to fetal sex, and will have the OB-GYN ordering the test similarly registered. Any lab or doctor offering to share fetal sex through NIPT is breaking the law — both the lab and the parents requesting disclosure can face criminal penalties under the Act.

This is not just bureaucracy. The PC-PNDT Act exists because of decades of female feticide in parts of India, and the sex ratio at birth in some states is still skewed enough that the law is actively enforced. The clinical purpose of NIPT in India is chromosomal screening for medical conditions, not for sex determination. If your reason for considering NIPT is to know the baby's sex, the answer in India is that no test will legally provide that information before birth, and NIPT is not a workaround. For the broader context of how pregnancy testing and law intersect for Indian women, see Is My Body Ready to Conceive? and TTC After 30 – A Calm Guide.

NIPT is a screening test that costs a meaningful sum of money, and like any test, it is only worth doing if the result would change something. If you would continue the pregnancy regardless of the result — for personal, religious, family or other reasons — then NIPT may not add value for you. That is a valid position, and declining screening is not a failure of antenatal care. The anomaly scan at 18 to 20 weeks still happens, the rest of the antenatal care continues, and the absence of an NIPT result does not change the routine pathway.

There are also clinical situations where going directly to a diagnostic test is the better choice rather than screening first. If the NT scan at 11 to 13 weeks shows a markedly abnormal nuchal translucency (above 3.5 mm) or an absent nasal bone, or if there is a previous pregnancy with a confirmed chromosomal abnormality, the probability of a chromosomal condition in this pregnancy is high enough that CVS at 11 to 14 weeks gives a definitive answer faster than waiting for an NIPT result and then needing CVS anyway. The same logic applies to certain ultrasound findings later in pregnancy that point strongly to a specific condition. These decisions are best made with your OB-GYN, ideally with input from a maternal-fetal medicine specialist or genetic counsellor.

NIPT is also not the right test if your concern is a single-gene disorder (such as thalassaemia, sickle cell disease or cystic fibrosis), a structural defect, or a metabolic condition — those need targeted carrier testing, the anomaly scan, or specific gene panels rather than chromosomal screening. If you have already had a pregnancy loss and are weighing the next pregnancy carefully, see miscarriage-types-and-recovery-india for the wider context within which screening decisions sit.

The practical sequence is straightforward. You visit the lab or collection centre, a single tube of blood is drawn from the arm (the same as any routine blood test, no fasting required), and the sample is shipped to the central sequencing facility. Sequencing and bioinformatics take a few days, quality checks and result generation take another few days, and the report is released to your OB-GYN somewhere between day 7 and day 14. The report is then discussed with you at a follow-up visit; some labs also offer a free or paid genetic counselling session with the report.

A low-risk result is reassuring — it does not need any further action, and the rest of antenatal care continues as planned. A high-risk result triggers a structured pathway: a counselling visit to explain what the specific result means in terms of probability (not certainty), an offer of diagnostic confirmation with CVS or amniocentesis, and time and space to decide whether to pursue confirmation. No major decisions about the pregnancy are made on the screening result alone.

A no-call result — where the lab cannot give a clear answer, often because fetal fraction is too low — usually means a repeat blood sample a few weeks later. If the no-call persists across two samples, the conversation usually shifts to either accepting a non-result or moving directly to a diagnostic test if the underlying clinical concern is high enough.

NIPT is a genuinely useful tool in 2026 Indian obstetric practice. It is more accurate than the older serum markers for the conditions it screens for, it carries no procedural risk because it is just a blood draw, it can be done early in pregnancy, and it spares many women an unnecessary amniocentesis by reducing false-positive screening results. For women with a higher baseline chromosomal risk — advanced maternal age, an abnormal NT scan, a high-risk serum marker, a previous chromosomal pregnancy, IVF, twins — the case for NIPT over the older screens is clear, and the cost usually justifies itself.

For women with a low baseline risk who want the reassurance of a high-accuracy early screen and can afford the out-of-pocket cost, NIPT is a reasonable elective choice. For women who would continue the pregnancy regardless of the result, NIPT may not add value over the standard double marker plus anomaly scan pathway, and that is a perfectly valid place to stop.

What NIPT is not is a replacement for the anomaly scan, a substitute for diagnostic confirmation after a high-risk result, a way to learn the baby's sex in India, or a guarantee of a healthy baby. Used within its actual capabilities — chromosomal screening for a defined panel, with PC-PNDT-compliant reporting, with diagnostic confirmation for any abnormal result, and alongside the routine scans and care of any pregnancy — NIPT is one part of a complete antenatal plan, not the whole plan.